Blood brain barrier (BBB)
This study attempts to replicate the findings published in Nature Medicine by Nation and colleagues (2019). By using a large observational cohort (DZNE - Longitudinal Cognitive Impairment and Dementia Study; DELCODE) consisting of cognitively healthy individuals, individuals with subjective cognitive decline, mild cognitive impairment, and dementia due to Alzheimer's disease, an association between the blood-brain barrier and cognitive dysfunction is investigated. The integrity of the blood-brain barrier is investigated by using a novel MRI protocol as well as a novel biomarker in the cerebrospinal fluid.
People with MCI, subjective cognitive dementia, and dementia due to AD
132
blood draw, in clinic visits, invasive lumbar puncture, discomfort, recovery time in clinic to decrease risk of spinal fluid leakage , MRI scan
MRI machine, MRI technician, physician who can preform a lumbar puncture as well as a clinic designed for this testing, equipped lab (e.g., centrifuge), a way to measure the peptide (e.g., mass spectrometer, protein assay kit, ELISA, or western blot), phlebotomist
Charite University, Berlin, Germany
“The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease.” ClinicalTrials.gov. Access October 11, 2019. https://clinicaltrials.gov/ct2/show/NCT04093882?term=biomarker&recrs=adf&cond=Alzheimer+Disease&draw=6&rank=30